Expanded access program
62 evidence topics · 16 sources
Objective
Purpose of the original Rush expanded access protocol
“The protocol was developed to allow access to treatment for 001-01, who was showing relatively rapid disease progression and could not enroll in the phase 1/2a trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this study, the long-term effects of intrathecal HPβCD treatment for 2.5–3 years in humans with NPC were evaluated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Objective of the survival analysis by baseline disease burden
Objective of the prompt versus delayed treatment analysis
Objective of the combination therapy analysis
Location and study date
Expanded access protocol under IND 119856 at Rush University Medical Center, with drug provided by Mandos Health
“Intrathecal adrabetadex was administered under an expanded access protocol (IND 119856) and reliance agreement with NIH approved by the Rush University Medical Center IRB.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“EBK has received funds to consult and/or run clinical trials for commercial programs focused in NPC including Orphazyme, Zevra, Intrabio, Vtesse, Sucampo, Mallinckrodt, and runs an expanded access program for adrabetadex for which drug is provided by Mandos Health.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Institutional review board approval of the original protocol
Evaluation sites for expanded access participants in a biomarker study
Agreement with the FDA to continue the program beyond October 2021
Data cutoff of the combination therapy analysis
Study design
Label description of the expanded access program data
Intermediate-size patient population IND modeled on the phase 1/2a trial
“In order to treat her brother, 001-02, at the same time, the expanded access application was submitted to FDA as an intermediate-size patient population IND (IND 119856).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The protocol was designed to parallel the ongoing phase 1/2a trial, with 2-week dosing intervals as opposed to the 4-week intervals in the phase 1/2a trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We report here results from three patients treated with IT HPβCD via expanded access through an intermediate-size patient population IND.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety data collection in the combination therapy analysis
Prompt versus delayed treatment analysis of participants treated for at least 5 years
Survival analysis of pooled clinical study and expanded access participants by baseline disease burden
Sibling case report design
Eligibility criteria
Access for patients unable to enroll in trials
“These protocols included a natural history/observational study (NCT00344331), phase I/II and phase II/III studies of intrathecal VTS‐270/adrabetadex (NCT01747135 and NCT02534844), and an expanded access program for access to intrathecal VTS‐270/adrabetadex for patients with NPC1 who were unable to enroll in trials (IND 119856).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trial ineligibility of the first three expanded access patients
“At age 13 she screened for the phase 1/2a trial of IT HPβCD but was ineligible due to multiple anticonvulsants and vagal nerve stimulator use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“He was not able to enter the phase 1/2a trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“001-03 could not enter the phase 1/2a trial of HPβCD as it was closed when the family requested screening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Continued-benefit criteria for participants leaving the VTS301 trial, December 2021
Age criteria expanded to 3 months to 25 years, September 2024
Treatment
Label dosing in the expanded access program
Titration ceilings of the initial and revised expanded access protocols
Formulation, route, and dose range of the original Rush protocol
“A formulation of HPβCD with a specific chemical fingerprint was obtained from Janssen Research & Development, LLC initially and then Vtesse, Inc. (VTS-270, same formulation) and in all cases was administered by intrathecal infusion via lumbar puncture every two weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The initial protocol was written to dose escalate from 200 mg to 400 mg (accepted dose range at the time) over 4 months based on safety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The protocol was amended to allow dosing based on tolerability within a range from 200 mg-1200 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Doses and dosing intervals in a long-term treated cohort
“Intrathecal doses of adrabetadex at the time of sample collection ranged from 300–900 mg (mean 660 ± 216 mg).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interval between doses was either 2 weeks (n=6) or 4 weeks (n=4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Doses in the sibling case report
Study outcomes
Rationale for using rescored 4-domain NPC clinical severity scale as the disease progression outcome
Domains of the rescored 4-domain scale and burden quartiles
Hearing items excluded from severity scores because of cyclodextrin ototoxicity
“Hearing items were scored at baseline to evaluate disease severity, but efficacy assessment scores excluded hearing and auditory brainstem response items, as hearing loss is a known side effect of HPβCD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Participants enrolled, December 2021
| Field | Dashboard |
|---|---|
| Current patients enrolled in Expanded Access Program | “50 patients” |
Participants in the survival analysis by baseline disease burden
Participants in the long-term 24(S)-hydroxycholesterol study
Description of analysis sets
Baseline definitions and survival comparisons in the disease burden analysis
Combination therapy analysis groups and observation time
| Group (participants) | Definition |
|---|---|
| Adrabetadex first (28) | “Participants who started adrabetadex prior to adding levacetylleucine and/or arimoclomol” |
| Any combination exposure (33) | “Participants who had exposure to levacetylleucine and/or arimoclomol at any point” |
| No combination after adrabetadex (53) | “Participants with no record of starting arimoclomol and/or levacetylleucine after starting adrabetadex” |
Statistical tests in the long-term 24(S)-hydroxycholesterol study
Results
Participant disposition
Duration of treatment and follow-up in the 2026 analyses
Time on treatment in the long-term 24(S)-hydroxycholesterol cohort
Time since first dose and discontinuations in the expanded access program
| Measure | All EAP (n=86) |
|---|---|
| Time since first treatment dose, median [IQR], months | “52.8 [15.4, 74.2]” |
| TEAE leading to discontinuation, n (%) | “3 (3.5)” |
| TEAE leading to death, n (%) | “6 (7.0)” |
Baseline characteristics
Baseline characteristics of all expanded access participants
| Characteristic | All EAP (N=86) |
|---|---|
| Neurological onset <2 years, n (%) | “26 (30.2)” |
| Neurological onset 2 to 6 years, n (%) | “23 (26.7)” |
| Neurological onset ≥6 years, n (%) | “29 (33.7)” |
| Age at onset missing, n (%) | “8 (9.3)” |
| Age at neurological symptom onset, median (Q1, Q3), years (n=78) | “3.5 (1.5, 7.0)” |
| Age at adrabetadex treatment start, median (Q1, Q3), years (n=78) | “8.0 (3.0, 20.0)” |
| Male, n (%) | “51 (59.3)” |
| Female, n (%) | “34 (39.5)” |
| White, n (%) | “76 (88.4)” |
| Miglustat use at baseline, yes, n (%) | “33 (38.4)” |
| Miglustat use at baseline, no, n (%) | “46 (53.5)” |
Baseline characteristics of treated participants with infantile onset in the disease burden analysis
| Characteristic | Overall (N=76) |
|---|---|
| Neurological onset <2 years, n (%) | “33 (43.4)” |
| Neurological onset 2 to <6 years, n (%) | “43 (56.6)” |
| Age at neurological symptom onset, mean (SD), years | “2.5 (1.56)” |
| Age at adrabetadex treatment start, mean (SD), years | “7.7 (5.56)” |
| Age at adrabetadex treatment start, median (Q1, Q3), years | “6.2 (3.2, 10.8)” |
| Male, n (%) | “41 (53.9)” |
| White, n (%) | “66 (86.8)” |
| Baseline R4DNPCCSS, mean (SD) | “7.2 (5.06)” |
| Baseline R4DNPCCSS, median (Q1, Q3) | “7.0 (3.0, 10.0)” |
Baseline characteristics by time from onset to treatment
| Characteristic | Treatment initiation <1 year from onset (n=9) | Treatment initiation ≥1 year from onset (n=16) |
|---|---|---|
| Age at neurological symptom onset, mean (SD), years | “2.11 (1.563)” | “2.65 (1.494)” |
| Age at adrabetadex treatment start, mean (SD), years | “2.70 (1.614)” | “7.15 (3.838)” |
| Duration from onset to treatment, mean (SD), years | “0.59 (0.324)” | “4.50 (3.308)” |
| Miglustat use at baseline, yes, n (%) | “1 (11.1)” | “9 (56.3)” |
| Baseline R4DNPCCSS, median (Q1, Q3) | “1.50 (0.50, 2.50)” | “5.00 (2.00, 10.00)” |
| Duration of treatment exposure, mean (SD), weeks | “348.37 (54.297)” | “397.23 (93.427)” |
Characteristics of the long-term 24(S)-hydroxycholesterol cohort
“This cohort included 7 males and 3 females.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean and median age were 20.1 ± 7.8 and 24.1(range 8.7–29.0) years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean and median ANO were 7.3 ± 4.1 and 6.8 (range 0–13) years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Characteristics of the first three expanded access patients at entry
Efficacy results
Company-presented survival by baseline disease burden, pooled clinical study and expanded access participants
| Median OS (95% CI), months | Minimal quartile | Mild quartile | Moderate quartile | Severe quartile |
|---|---|---|---|---|
| Adrabetadex-treated participants | “NE (NE, NE)” | “136 (88, NE)” | “75 (60, NE)” | “55 (12, NE)” |
| Untreated cohort | “99 (39, 192)” | “111 (62, NE)” | “62 (28, NE)” | “29 (11, NE)” |
Company summary of the CNS 2026 survival and progression analyses
Time from onset to treatment in the prompt and delayed treatment groups
Sibling case report: early and delayed treatment initiation
Neurological outcomes in the first three expanded access patients over 2.5 to 3 years
“No worsening in any domain except eye movements (vertical pursuit gain) was seen for any of the three patients, and in the other domains, improved scores on measures were seen over time for one or more patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The NSS showed stable to slightly improved ratings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All three patients have shown substantial improvement in oral and pharyngeal phases of swallowing function as rated by the MBSImp (Table 4; Figure 6) and PAS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CSF 24(S)-hydroxycholesterol response after more than 4 years of treatment
“Mean pre-drug administration CSF 24(S)OHC level was 0.27 ± 0.20 ng/ml.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean CSF 24OHC level 48 hours after IT adrabetadex administration increased to 0.43 ± 0.22 ng/ml.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This 1.6-fold average increase was significant (p=0.0289, paired t-test).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“24(S)OHC levels increased in 7 of the 10 individuals and the mean increase was 0.28 ± 0.34 ng/ml.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CSF neurofilament light chain in a cohort including expanded access participants
“The population was derived from an observational/natural history study at the NIH Clinical Center in Bethesda, Maryland (NCT00001367), from a phase I/II intrathecal trial of adrabetadex (NCT01747135), from a phase II/III intrathecal trial of adrabetadex (NCT02534844) and from individuals receiving intrathecal adrabetadex through an expanded access program (IND 119856).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By the last visit, 49 (42.2%) were on HPβCD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over time, we did not observe a protective effect of HPβCD on NfL levels (OR=1.25, 95% CI 0.99–1.58) (Supplementary Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In fact, when adjusting the longitudinal data for the protective effect of miglustat, HPβCD was associated with increased NfL levels (OR=1.35, 95% CI 1.09–1.67).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CSF total tau in a cohort including expanded access participants
“The data set consisted of 262 measurements from 101 individuals with NPC1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intrathecal 2HPβCD therapy was associated with a reduction in CSF total Tau levels of 19% (FDR‐adjusted p = 0.008).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CSF neuron-specific enolase in expanded access participants
“Paired CSF and serum samples were obtained from a subset of ten participants receiving IT HPβCD every 2–4 weeks under the EAP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants on IT HPβCD experienced an average decrease of 3.7 ± 2.9 ng/mL in CSF NSE levels per year, while those not on IT HPβCD showed an average annual increase of 2.6 ± 2.5 ng/mL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This difference was statistically significant (p = .0317), suggesting that IT HPβCD treatment may reduce CSF NSE levels over time (figure 4b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
School and work functioning in the first three expanded access patients
“001-02 has had stable school performance and graduated high school with a regular curriculum and some accommodations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“001-03 has had stable performance in a community college and subsequent job training program and does well with office work.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Treatment-emergent adverse events in the expanded access program by combination therapy group
| Measure | Adrabetadex first, adrabetadex-only period (n=28) | Any combination exposure, combination period (n=33) | No combination after adrabetadex (n=53) | All EAP (n=86) |
|---|---|---|---|---|
| With ≥1 TEAE (any grade), n (%) | “28 (100)” | “23 (69.7)” | “48 (90.6)” | “81 (94.2)” |
| Leading to death, n (%) | “0” | “1 (3.0)” | “5 (9.4)” | “6 (7.0)” |
| Serious AEs, n (%) | “13 (46.4)” | “8 (24.2)” | “24 (45.3)” | “41 (47.7)” |
| Grade ≥3, n (%) | “9 (32.1)” | “6 (18.2)” | “21 (39.6)” | “33 (38.4)” |
| TEAEs of interest, n (%) | “22 (78.6)” | “9 (27.3)” | “35 (66.0)” | “62 (72.1)” |
| Ataxia, n (%) | “10 (35.7)” | “5 (15.2)” | “23 (43.4)” | “37 (43.0)” |
| Fatigue, n (%) | “17 (60.7)” | “7 (21.2)” | “25 (47.2)” | “47 (54.7)” |
| Hearing impairment, n (%) | “10 (35.7)” | “2 (6.1)” | “15 (28.3)” | “26 (30.2)” |
Hearing loss, post-dose ataxia and tiredness, and lumbar puncture events in the first three expanded access patients
“Aside from hearing changes and post-dose tiredness/ataxia known to be associated with higher doses of HPβCD, adverse events have been predominantly unrelated to the lumbar punctures (LPs) or HPβCD (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Post-LP headaches and nausea in 001-01 and 001-02 for several initial doses essentially resolved after switching to the Whitacre needle for LPs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was persistent ataxia and tiredness at 1200 mg (Table 3) and milder post-dose ataxia and tiredness at 900 mg, lasting 3–7 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“She continues on a dose of 300 mg (Table 3) due to an incremental hearing loss and tinnitus with each of three 400 mg doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“001-03 has an unusual sensitivity to hearing loss with HPβCD, as the extent of hearing loss seen in this patient at the 400 mg dose, is not known to have been observed in any other patient worldwide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: design limitations of the expanded access program analyses
- Control and setting: the original report of three patients names as limitations “the lack of a control group” and treatment through an expanded access protocol with likely more confounding changes from optimizing support and other treatments than in a clinical trial. Enrollment required that participants be ineligible for all currently enrolling clinical trials.
- Population counts: the prescribing information describes 85 participants (71 treatment-naïve and 14 previously treated) with a mean (SD) treatment duration of 44 (32) months.
- Dosing: doses started at 200 mg or 400 mg based on age, with titration up to 1200 mg in the initial protocol or 900 mg in the later revision, and dose adjustments were allowed.
- External comparison and analysis sets: the survival analysis by baseline disease burden compared 80 adrabetadex-treated participants with I-NPC (neurological onset <6 years) from clinical studies or the expanded access program with an untreated cohort of 44 from the NIH natural history study. Four treated participants without a baseline R4DNPCCSS score were excluded, leaving 76. Baseline was the last observation before the first dose for treated participants and the first available observation for the untreated cohort, and the authors state that “no matching procedure was performed between treated and untreated participants.”
- Prompt versus delayed treatment: the analysis included only participants with onset <6 years of age who had sustained treatment for at least 5 years, 9 with treatment initiation <1 year and 16 with initiation ≥1 year from onset, and miglustat use at baseline was 1 (11.1%) and 9 (56.3%), respectively. The company compared progression in these 25 participants with published natural history data.
- Combination therapy analysis: participants exposed to combination therapy had a shorter time since first treatment dose, as most started those therapies when they became commercially available at the end of 2024. Safety data were collected only while participants were in the study and receiving adrabetadex, and were not available for other NPC therapies received before enrollment.
- Concomitant miglustat: all three patients in the original report went on miglustat at the same age as diagnosis, and its authors state that an effect of miglustat or of the combination on progression cannot be ruled out. In the CSF neuron-specific enolase study, most participants receiving intrathecal HPβCD were also on miglustat, which the authors state makes it challenging to attribute the decrease to HPβCD alone.
- Sample size: the long-term 24(S)-hydroxycholesterol study included 10 individuals, and its authors state that its conclusions are limited by its small size; the CSF neuron-specific enolase study used a subset of ten expanded access participants.
Authors' limitations of the original expanded access report
“Limitations of this work include the lack of a control group and treatment through an expanded access protocol in which there are likely more confounding changes due to optimizing support and other treatments than would be seen in a clinical trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“it is impossible to rule out an effect on progression of the Miglustat or a combined effect of Miglustat and HPβCD, which target lipid storage in NPC via different mechanisms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unmatched comparison with the untreated cohort in the disease burden analysis
Shorter observation time in the combination therapy group
Small cohort size and concomitant miglustat in the biomarker studies
“The conclusions of this study are limited by its small size; however, the data presented herein suggest that 24(S)OHC remains a robust proximal pharmacodynamic biomarker in individuals who have been treated for over four years with IT adrabetadex.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote